Gillheeney Gary S. 4
4 · Organogenesis Holdings Inc. · Filed Dec 12, 2024
Insider Transaction Report
Form 4
Gillheeney Gary S.
DirectorPresident and CEO
Transactions
- Sale
Class A Common Stock
2024-12-11$3.64/sh−157,448$573,111→ 3,143,753 total - Sale
Class A Common Stock
2024-12-10$3.64/sh−58,525$213,031→ 3,301,201 total - Sale
Class A Common Stock
2024-12-12$3.55/sh−43,359$153,924→ 3,100,394 total
Footnotes (4)
- [F1]The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.4531 to $3.74, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.72, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.495 to $3.65, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.